Bausch Health Companies Inc Stock Price, News & Analysis

Bausch Health reported fourth-quarter revenues of $2.2 billion for 2022, flat compared to 2021 but up 4% organically. Full-year revenues were $8.1 billion, down 4% from 2021, but up 2% organically. The company reduced debt by $464 million in Q4 2022 and $3.2 billion since Bausch + Lomb's IPO. Operating loss for Q4 was $236 million due to a goodwill impairment charge. However, net loss for the year improved to $225 million from $948 million in 2021. Bausch Health forecasts 2023 revenues (excl. B+L) between $4.45 and $4.6 billion.

KBRA's fourth-quarter 2022 U.S. Bank Compendium offers insights into the U.S. banking sector, analyzing performance metrics and credit quality indicators for banks under KBRA's long-term ratings. The report highlights loan quality, loss absorption capacity, and key trends affecting bank performance amidst a low problem loan environment. It also details the top 10 banks with lowest cost deposit franchises and significant changes in financial ratios. Additionally, the Compendium features a quarterly ESG Bulletin, and a supplement with 158 debt issues from rated banks.

Bausch Health (NYSE/TSX:BHC) announced the opening of the 2023 Salix Gastrointestinal Health Scholars Program, offering scholarships of up to $10,000 to 10 students living with gastrointestinal (GI) diseases. This initiative, now in its fourth year, aims to support students in pursuing higher education. Applicants can apply until May 15, 2023, and must submit essays detailing their experiences with GI conditions. The program comprises various categories, including awards for undergraduate and graduate students, as well as scholarships for working and single parents. Recipients will be notified in summer 2023.

Bausch Health Companies Inc. (BHC) is set to announce its fourth-quarter and full-year financial results on February 23, 2023. The announcement will be followed by a conference call at 8:00 a.m. U.S. EST to discuss the results and provide a business update. Investors can access all related materials on the Investor Relations section of the Bausch Health website. A replay of the call will also be available there. Bausch Health operates globally, specializing in various pharmaceutical sectors, including gastroenterology, neurology, and eye health.

Bausch Health Companies (NYSE/TSX:BHC) announced a favorable ruling from the US District Court for the District of New Jersey regarding its products DUOBRII and BRYHALI. The court upheld the validity of all asserted patents, preventing the approval of generics by Padagis Israel Pharmaceuticals until the patents expire in 2031 and 2036, respectively. This decision reinforces Bausch Health's commitment to its patent portfolio and the strength of its intellectual property. DUOBRII and BRYHALI are both topical medications for treating plaque psoriasis.

Salix Pharmaceuticals, part of Bausch Health (NYSE:BHC), has launched new social media initiatives for Constipation Awareness Month in December. This campaign raises awareness about constipation-related diseases including opioid-induced constipation, irritable bowel syndrome with constipation, and chronic idiopathic constipation. Salix's efforts include collaborations with influencers and extensive educational content that reached over 240 million consumers in 2022. The company aims to enhance public understanding of gastrointestinal disorders and will continue working with patient advocacy groups to support education and research in 2023.

Bausch Health Companies Inc. (NYSE:BHC) has declared 1261229 B.C. Ltd. as an unrestricted subsidiary, which controls 88.7% of Bausch + Lomb Corporation. This change means Bausch + Lomb and its subsidiaries are no longer bound by Bausch Health's debt covenants. The company is actively exploring options to optimize stakeholder value, focusing on balance sheet and liquidity strategies. These developments may impact the company's financial flexibility and strategic positioning moving forward.

KBRA has published its third-quarter 2022 U.S. Bank Compendium and 2023 Sector Outlook, analyzing results for U.S. banks. The report acknowledges the resilience of rated banks amid tightening economic conditions, citing improved capital profiles and higher loss buffers. Despite economic uncertainties, the report maintains a Stable Outlook for the U.S. banking industry. Key metrics, trends, and the top performing banks based on deposit costs and reserves are discussed. The Compendium also includes a quarterly ESG Bulletin featuring Berkshire Hills Bancorp, Inc. (BHLB).

Bausch Health Companies Inc. (NYSE:BHC) announced the presentation of a de novo abstract at The Liver Meeting® 2022 in Washington, D.C., from November 4-8. The abstract is titled "Rifaximin Plus Lactulose Versus Lactulose Alone for Reducing the Risk of Overt Hepatic Encephalopathy Recurrence: A Pooled Subgroup Analysis." XIFAXAN® (rifaximin) is indicated for the reduction of overt hepatic encephalopathy recurrence and treatment of irritable bowel syndrome with diarrhea. The company emphasizes safety information related to XIFAXAN use.